Guru Fundamental Report for JNJ

Johnson & Johnson (JNJ) received a 77% score from Validea's P/B Growth Investor model, based on Partha Mohanram's strategy for identifying low book-to-market stocks with sustained growth potential. While JNJ, a large-cap biotechnology and drugs stock, passed most of the model's fundamental criteria, its score fell just below the 80% threshold for investor interest, notably failing on metrics related to advertising and research and development expenditures relative to assets, which are crucial for long-term growth.

Analysis

Johnson & Johnson (JNJ) exhibits a mixed profile according to Validea's P/B Growth Investor model, a quantitative strategy designed by Partha Mohanram to identify low book-to-market stocks with sustained growth potential. JNJ achieved a score of 77%, which is proximate to but falls short of the 80% threshold that typically signals notable interest from the model. The analysis indicates strength in core financial health, as JNJ passed criteria related to its book-to-market ratio, return on assets (ROA), cash flow generation, and the stability of both its ROA and sales. However, the model flagged two critical failures for a growth-oriented assessment: JNJ's expenditure on both Advertising to Assets and Research and Development to Assets was deemed insufficient. These shortfalls are particularly significant within the Biotechnology & Drugs industry, where R&D and marketing are primary drivers of future revenue streams, suggesting JNJ may not fit the aggressive growth profile sought by this specific investment framework despite its operational stability.

Key Decisions for Investors

• Growth-oriented investors should note that JNJ's 77% score and failure on R&D and advertising metrics suggest it may not meet the criteria for a high-growth trajectory under this specific model.
• Investors focused on quality and stability might view the positive ratings on return on assets, cash flow, and sales variance as evidence of a fundamentally sound, large-cap holding.
• It is prudent to further investigate whether the lower R&D and advertising expenditures relative to assets are a sign of disciplined capital allocation or a potential long-term risk to JNJ's growth pipeline and market position.